Advances in Surgery and Transplantation for Liver Cancer

Dear Colleagues,

Liver cancer is one of the most common malignancies in the world. It is usually difficult to treat cancer in the liver because the liver is recognized as an immune privilege organ. Moreover, the liver is easily affected by viral/non-viral pathogens, which induce liver inflammation, fibrosis, or even cirrhosis. All these conditions result in difficulty in liver cancer treatment. Currently, many therapeutic modalities can be applied to treat liver cancer. Surgery and transplantation remain the most effective treatments to yield better outcomes than other modalities. However, surgery and transplantation are restricted to the treatment of liver cancer in its earlier stage. Subsequently, only a minority of liver cancer patients can be cured.

Recently, immune checkpoint inhibitors (ICI) are applied to treat liver cancer with promising effects. A combination of ICI and molecular targeting therapy can achieve about 30% of the objective response rate in advanced liver cancer, and the tumor stages can be downgraded. Sequential liver surgery and transplantation to cure the patients then become possible. However, the clinical evidence is still limited. The aspects of liver cancer treatment are altered when immunotherapy is introduced to treat liver cancer. The aim of this Special Issue, “Advances in Surgery and Transplantation for Liver Cancer”, is to present all aspects of advances in liver surgery and transplantation. For this Special Issue, we welcome the submission of any work that discusses advances in liver cancer treatment. Topics of interest include, but are not limit to, technical advances, outcome prediction or improvement, neoadjuvant/adjuvant therapy, translation medicine, and immunological consideration in liver surgery and transplantation for liver cancer treatment.

Prof. Dr. Wei-Chen Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.